IntelGenx Technologies Corp. (IGX.TO)

0,2600 +0,0100 (+4,00%) Ab 09:30AM EDT. Markt geöffnet.

IntelGenx Technologies Corp.

6420 Abrams
Ville Saint Laurent
Montreal, QC H4S 1Y2
Canada
514 331 7440
https://www.intelgenx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Dwight Gorham	Chief Executive Officer	317,68k	N/A	1958
Mr. André Godin C.A., CPA, CA, CPA	President & CFO	360,47k	N/A	1964
Mr. Tommy Kenny J.D., L.L.B., M.Sc.	Senior VP & General Counsel	210,28k	N/A	1987
Ms. Nadine Paiement M.Sc.	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	215,62k	N/A	1977
Ms. Karen Kalayajian CPA	Vice President of Finance & Administration	N/A	N/A	1980
Stephen Kilmer	Investor Relations Officer	N/A	N/A	N/A
Ms. Ingrid Zerbe	Corporate Secretary	N/A	N/A	1954
Zenoz Nina Pourhassan	VP of Quality Operations of Subsidiary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Corporate Governance

IntelGenx Technologies Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.